Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Vanda Pharmaceuticals (VNDA)

Vanda Pharmaceuticals (VNDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 219,216
  • Shares Outstanding, K 57,537
  • Annual Sales, $ 192,640 K
  • Annual Income, $ 2,510 K
  • 60-Month Beta 0.77
  • Price/Sales 1.13
  • Price/Cash Flow N/A
  • Price/Book 0.40
Trade VNDA with:

Options Overview Details

View History
  • Implied Volatility 73.85% ( -10.15%)
  • Historical Volatility 62.12%
  • IV Percentile 83%
  • IV Rank 52.25%
  • IV High 132.67% on 01/02/24
  • IV Low 9.48% on 03/22/23
  • Put/Call Vol Ratio 0.39
  • Today's Volume 623
  • Volume Avg (30-Day) 630
  • Put/Call OI Ratio 0.25
  • Today's Open Interest 9,651
  • Open Int (30-Day) 8,969

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate 0.05
  • Number of Estimates 1
  • High Estimate 0.05
  • Low Estimate 0.05
  • Prior Year 0.06
  • Growth Rate Est. (year over year) -16.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +0.81%
on 03/18/24
4.76 -21.22%
on 02/27/24
-0.63 (-14.38%)
since 02/16/24
3-Month
3.46 +8.38%
on 02/06/24
4.76 -21.22%
on 02/27/24
-0.11 (-2.85%)
since 12/18/23
52-Week
3.30 +13.81%
on 11/10/23
7.00 -46.43%
on 05/05/23
-2.77 (-42.48%)
since 03/17/23

Most Recent Stories

More News
Vanda: Q4 Earnings Snapshot

Vanda: Q4 Earnings Snapshot

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced its intention to file a petition for a writ of certiorari in its HETLIOZ®...

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies Inaugural Biotech...

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals Announces Participation in the H.C. Wainwright Global Investment Conference

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the H.C. Wainwright Global Investment...

VNDA : 3.75 (-1.57%)
Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday

The pharmaceutical company's stock hit another 52-week low.

VNDA : 3.75 (-1.57%)
Vanda: Q2 Earnings Snapshot

Vanda: Q2 Earnings Snapshot

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals Reports Second Quarter 2023 Financial Results

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2023....

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals to Announce Second Quarter 2023 Financial Results on July 27, 2023

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2023 on Thursday, July 27,...

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals Announces Participation in the Jefferies 2023 Global Healthcare Conference

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Jefferies 2023 Global Healthcare...

VNDA : 3.75 (-1.57%)
Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

/PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced participation at SLEEP 2023, to be held in Indianapolis, IN from June 3 – 7,...

VNDA : 3.75 (-1.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. It is developing important new medicines to improve the lives of patients. It uses new technologies, including genetics...

See More

Key Turning Points

3rd Resistance Point 3.94
2nd Resistance Point 3.89
1st Resistance Point 3.82
Last Price 3.75
1st Support Level 3.70
2nd Support Level 3.65
3rd Support Level 3.58

See More

52-Week High 7.00
Fibonacci 61.8% 5.58
Fibonacci 50% 5.15
Fibonacci 38.2% 4.71
Last Price 3.75
52-Week Low 3.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar